Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose-Finding, Safety Study of Oral AMXT 1501 Dicaprate and Difluoromethylornithine (DFMO) in Patients With Advanced Solid Tumors

NCT03536728 is registered in ClinicalTrials.gov with Aminex Therapeutics, Inc. as lead sponsor.

NCT NCT03536728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03536728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose-Finding, Safety Study of Oral AMXT 1501 Dicaprate and Difluoromethylornithine (DFMO) in Patients With Advanced Solid Tumors
Lead sponsor
Aminex Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 12, 2018
Completion date
April 21, 2023
Enrollment
56 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, cancer, solid carcinoma, solid tumor